Back
Monopar Therapeutics 10K Form
Buy
65
MNPR
Monopar Therapeutics
Last Price:
15.69
Seasonality Move:
4.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive MNPR News And Ratings
See the #1 stock for the next 7 days that we like better than MNPR
MNPR Financial Statistics
Sales & Book Value
| Annual Sales: | -- |
|---|---|
| Cash Flow: | $-1.68M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.73 |
| Price / Book: | 9.1 |
Profitability
| EPS (TTM): | -2.30000 |
|---|---|
| Net Income (TTM): | $-7.12M |
| Gross Margin: | -- |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Monopar Therapeutics Earnings Forecast
Key Monopar Therapeutics Financial Ratios
- Per Share Earnings over the last 8 years have been positive in 2 years.
Monopar Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | MNPR |
| Website: | monopartx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
MNPR Technical Analysis vs Fundamental Analysis
Buy
65
Monopar Therapeutics (MNPR)
is a Buy
Is Monopar Therapeutics a Buy or a Sell?
-
Monopar Therapeutics stock is rated a Buy
The current Monopar Therapeutics [MNPR] share price is $15.75. The Score for MNPR is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.